Is Palisade Bio Inc (NASDAQ: PALI) a smart move or a risky gamble for your portfolio?

In the latest trading session,, 2.26 million Palisade Bio Inc (NASDAQ:PALI) shares changed hands as the company’s beta touched 1.38. With the company’s most recent per share price at $0.66 changed hands at -$0.05 or -6.37% at last look, the market valuation stands at $3.18M. PALI’s current price is a discount, trading about -680.3% off its 52-week high of $5.15. The share price had its 52-week low at $0.60, which suggests the last value was 9.09% up since then. When we look at Palisade Bio Inc’s average trading volume, we note the 10-day average is 0.17 million shares, with the 3-month average coming to 384.09K.

Analysts gave the Palisade Bio Inc (PALI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PALI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Palisade Bio Inc’s EPS for the current quarter is expected to be -0.55.

Palisade Bio Inc (NASDAQ:PALI) trade information

Instantly PALI was in red as seen in intraday trades today. With action -9.86%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -59.79%, with the 5-day performance at -9.86% in the red. However, in the 30-day time frame, Palisade Bio Inc (NASDAQ:PALI) is -12.09% down. Looking at the short shares, we see there were 0.18 million shares sold at short interest cover period of 0.51 days.

The consensus price target for the stock as assigned by Wall Street analysts is 1.5, meaning bulls need an upside of 56.0% from its recent market value. According to analyst projections, PALI’s forecast low is 1.5 with 1.5 as the target high. To hit the forecast high, the stock’s price needs a -127.27% plunge from its current level, while the stock would need to soar -127.27% for it to hit the projected low.

According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 77.35%. The 2025 estimates are for Palisade Bio Inc earnings to increase by 85.62%, but the outlook for the next 5-year period is at 55.06% per year.

PALI Dividends

Palisade Bio Inc is expected to release its next quarterly earnings report on 2025-May-11.

Palisade Bio Inc (NASDAQ:PALI)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.46% of Palisade Bio Inc shares while 5.43% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 5.46%.

Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 18.58 shares estimated at $12582.0 under it, the former controlled 0.39% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.09% of the shares, roughly 4.54 shares worth around $3071.0.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.